Explain the drug discovery process of Losartan?

Drug discovery process of Losartan

Saralasin is an octa-peptide counterpart of Ang II that replaces the amino acids Asp1, Ile5, and Phe8 with Ser1, Val5, and Ala8, respectively. It was created in the early 1970s. Saralasin was not suitable as a medication since it was not orally accessible, had a limited duration of action, and showed partial agonist activity.

As a result, the goal was to create a non-peptide compound with similar inhibitory and binding properties. A group at DuPont had already begun screening non-peptide Ang II mimics using available chemicals from chemical libraries at the time.